Literature DB >> 27012324

Pharmacology: Dabigatran specific antidote.

A Curto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27012324     DOI： 10.1038/sj.bdj.2016.201

Source DB:  PubMed          Journal:  Br Dent J        ISSN： 0007-0610            Impact factor:   1.626


× No keyword cloud information.
  3 in total

1.  Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation.

Authors:  Oliver Grottke; Markus Honickel; Joanne van Ryn; Hugo ten Cate; Rolf Rossaint; Henri M Spronk
Journal:  J Am Coll Cardiol       Date:  2015-09-29       Impact factor: 24.094

2.  Idarucizumab approved for reversal of anticoagulant effects of dabigatran.

Authors:  Kate Traynor
Journal:  Am J Health Syst Pharm       Date:  2015-12-01       Impact factor: 2.637

3.  A Prospective Cohort Study of Idarucizumab for Reversal of Dabigatran-Associated Hemorrhage.

Authors:  Robert M Starke; Ricardo J Komotar; E Sander Connolly
Journal:  Neurosurgery       Date:  2015-12       Impact factor: 4.654
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.